Importance of the pharmacological profile of thrombolytic agents in clinical practice

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Three thrombolytic agents are frequently used in the United States for treating patients with acute myocardial infarction: streptokinase, alteplase (tissue plasminogen activator [t-PA]), and anistreplase (anisoylated plasminogen-streptokinase activator complex [APSAC]). A fourth agent, urokinase, is occasionally used but clinical experience is considerably more limited with this agent. Streptokinase, alteplase, and anistreplase differ in a number of pharmacologic properties, which include half-life, enzymatic efficiency, and induction of platelet aggregation; these differences may be clinically important. For example, anistreplase and alteplase have high affinity for fibrin and bind to intravascular thrombi after intravenous administration, which may result in higher clot specificity. Anistreplase has the longest half-life of the 3 agents and, therefore, can be administered conveniently and quickly. Atteplase has a shorter half-life and heparin is generally a necessary adjunctive agent. These differences can be clinically significant in various settings and application of such theoretical advantages is just beginning.

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalThe American journal of cardiology
Volume68
Issue number16
DOIs
StatePublished - Dec 5 1991
Externally publishedYes

Fingerprint

Anistreplase
Fibrinolytic Agents
Tissue Plasminogen Activator
Pharmacology
Half-Life
Streptokinase
Urokinase-Type Plasminogen Activator
Fibrin
Platelet Aggregation
Intravenous Administration
Heparin
Thrombosis
Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Importance of the pharmacological profile of thrombolytic agents in clinical practice. / Alpert, Joseph S.

In: The American journal of cardiology, Vol. 68, No. 16, 05.12.1991, p. 3-7.

Research output: Contribution to journalArticle

@article{85a4e00efc6b40d4bc12ef6dcf0ac922,
title = "Importance of the pharmacological profile of thrombolytic agents in clinical practice",
abstract = "Three thrombolytic agents are frequently used in the United States for treating patients with acute myocardial infarction: streptokinase, alteplase (tissue plasminogen activator [t-PA]), and anistreplase (anisoylated plasminogen-streptokinase activator complex [APSAC]). A fourth agent, urokinase, is occasionally used but clinical experience is considerably more limited with this agent. Streptokinase, alteplase, and anistreplase differ in a number of pharmacologic properties, which include half-life, enzymatic efficiency, and induction of platelet aggregation; these differences may be clinically important. For example, anistreplase and alteplase have high affinity for fibrin and bind to intravascular thrombi after intravenous administration, which may result in higher clot specificity. Anistreplase has the longest half-life of the 3 agents and, therefore, can be administered conveniently and quickly. Atteplase has a shorter half-life and heparin is generally a necessary adjunctive agent. These differences can be clinically significant in various settings and application of such theoretical advantages is just beginning.",
author = "Alpert, {Joseph S}",
year = "1991",
month = "12",
day = "5",
doi = "10.1016/0002-9149(91)90298-Y",
language = "English (US)",
volume = "68",
pages = "3--7",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "16",

}

TY - JOUR

T1 - Importance of the pharmacological profile of thrombolytic agents in clinical practice

AU - Alpert, Joseph S

PY - 1991/12/5

Y1 - 1991/12/5

N2 - Three thrombolytic agents are frequently used in the United States for treating patients with acute myocardial infarction: streptokinase, alteplase (tissue plasminogen activator [t-PA]), and anistreplase (anisoylated plasminogen-streptokinase activator complex [APSAC]). A fourth agent, urokinase, is occasionally used but clinical experience is considerably more limited with this agent. Streptokinase, alteplase, and anistreplase differ in a number of pharmacologic properties, which include half-life, enzymatic efficiency, and induction of platelet aggregation; these differences may be clinically important. For example, anistreplase and alteplase have high affinity for fibrin and bind to intravascular thrombi after intravenous administration, which may result in higher clot specificity. Anistreplase has the longest half-life of the 3 agents and, therefore, can be administered conveniently and quickly. Atteplase has a shorter half-life and heparin is generally a necessary adjunctive agent. These differences can be clinically significant in various settings and application of such theoretical advantages is just beginning.

AB - Three thrombolytic agents are frequently used in the United States for treating patients with acute myocardial infarction: streptokinase, alteplase (tissue plasminogen activator [t-PA]), and anistreplase (anisoylated plasminogen-streptokinase activator complex [APSAC]). A fourth agent, urokinase, is occasionally used but clinical experience is considerably more limited with this agent. Streptokinase, alteplase, and anistreplase differ in a number of pharmacologic properties, which include half-life, enzymatic efficiency, and induction of platelet aggregation; these differences may be clinically important. For example, anistreplase and alteplase have high affinity for fibrin and bind to intravascular thrombi after intravenous administration, which may result in higher clot specificity. Anistreplase has the longest half-life of the 3 agents and, therefore, can be administered conveniently and quickly. Atteplase has a shorter half-life and heparin is generally a necessary adjunctive agent. These differences can be clinically significant in various settings and application of such theoretical advantages is just beginning.

UR - http://www.scopus.com/inward/record.url?scp=0026325612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026325612&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(91)90298-Y

DO - 10.1016/0002-9149(91)90298-Y

M3 - Article

C2 - 1746449

AN - SCOPUS:0026325612

VL - 68

SP - 3

EP - 7

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 16

ER -